Funding Clinical Trials

Funding Clinical Trials

Our Agency funds clinical trials testing promising stem cell or gene therapies for currently incurable diseases or disorders to help patients with unmet medical needs. For basic information about stem cell trials, visit our Clinical Trials 101 page. For a list of clinical trials that are a result of early-stage CIRM grants click here.

CIRM Clinical Dashboard

Disease Areas Investigatorsort descending Organization Phase Trial Status Targeted Enrollment Detail
Mehrdad Abedi University of California, Davis Phase 1/2 Recruiting 18
  • IPEX Syndrome
 Rosa Bacchetta Stanford University Phase 1 Recruiting 36
Krystof Bankiewicz Brain Neurotherapy Bio Phase 1 Active, not recruiting 11
  • Muscle Injury
 Peter Belafsky University of California, Davis Phase 1/2 Recruiting 62
  • Multiple Myeloma
 Rajesh Belani Poseida Therapeutics, Inc. Phase 1 Closed 105
  • Anemia
  • Bone Marrow Transplant and Viral Infection
 Alice Bertaina Stanford University Phase 1/2 Launching N/A
Francois Binette Lineage Cell Therapeutics Inc. Phase 1/2 Completed 25
Daniel Brennan Medeor Therapeutics, Inc. Phase 3 Active, not recruiting 30
Christine Brown City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 82
Pierre Caudrelier ExCellThera Inc. Phase 1 Withdrawn N/A
Thomas Chalberg Genascence Corporation Phase 1 Launching N/A
Mark Chao Forty Seven Inc. Phase 1/2 Completed 78
  • Leukemia, Acute Myeloid (AML)
 Mark Chao Forty Seven Inc. Phase 1 Active, not recruiting 258
Stephanie Cherqui University of California, San Diego Phase 1/2 Recruiting 6
  • Beta Thalassemia
 Bettina Cockroft Sangamo BioSciences, Inc. Phase 1/2 Completed 5
Pamela Contag BioEclipse Therapeutics INC. Phase 1 Recruiting 24
  • Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
 Morton Cowan University of California, San Francisco Phase 1 Recruiting 25
Steven Deeks University of California, San Francisco Phase 1/2 Launching N/A
  • Leukemia, Acute Myeloid (AML)
 Colleen Delaney Nohla Therapeutics Inc Phase 2 Closed 146
  • Corneal Damage
 Sophie Deng University of California, Los Angeles Phase 1 Recruiting 20
Robert Dillman Caladrius Biosciences Phase 3 Closed 4
Steven Dubinett University of California, Los Angeles Phase 1 Recruiting 24
  • Spina Bifida
 Diana Farmer University of California, Davis Phase 1 Recruiting 55
  • B cell cancers
 Paul Finnegan Angiocrine Bioscience, Inc. Phase 3 Recruiting 148
Howard Foyt ViaCyte, Inc. Phase 1/2 Closed 19
Stephen Gottschalk St. Jude Children's Research Hospital Phase 1/2 Recruiting 28
Anthony Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 414
Robert Hayes Immusoft Corporation Phase 1 Launching N/A
Mark Humayun University of Southern California Phase 1 Active, not recruiting 16
Manasi Jaiman ViaCyte, Inc. Phase 1/2 Active, not recruiting 75
Kristen Johnson Calibr Phase 1 Completed 60
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 42
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 10
William Kennedy Excision BioTherapeutics Phase 1 Recruiting 9
Ralph Kern BrainStorm Cell Therapeutics Phase 3 Completed 263
Ivan King Tachyon Therapeutics, Inc Phase 1 Launching N/A
Thomas Kipps University of California, San Diego Phase 1 Completed 26
Thomas Kipps University of California, San Diego Phase 1/2 Recruiting 138
Henry Klassen jCyte, Inc Phase 2 Completed 84
Henry Klassen University of California, Irvine Phase 1/2 Completed 28
Henry Klassen jCyte, Inc Phase 2 Completed 84
  • Immune Disease
  • Pediatrics
  • X-linked Chronic Granulomatous Disease
 Donald Kohn University of California, Los Angeles Phase 1/2 Active, not recruiting 16
Donald Kohn University of California, Los Angeles Phase 1 Recruiting 6
Donald Kohn University of California, Los Angeles Phase 2 Completed 10
Nancy Lane University of California, Davis Phase 1/2 Completed 58
Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 355
Jeffrey Lawson Humacyte, Inc. Phase 3 Recruiting 240
Jane Lebkowski Geron Corporation Phase 1 Completed 5
  • Pulmonary Hypertension
  • Vascular Disease
 Michael Lewis Cedars-Sinai Medical Center Phase 1/2 Active, not recruiting 26
Robert Lowsky Stanford University Phase 1 Active, not recruiting 15
Crystal Mackall Stanford University Phase 1 Recruiting 54
  • Alpha Thalassemia Major
 Tippi MacKenzie University of California, San Francisco Phase 1 Enrolling by invitation 10
Linda Marban Capricor, Inc Phase 2 Completed 25
  • COVID-19
 Michael Matthay University of California, San Francisco Phase 2 Active, not recruiting 120
Everett Meyer Stanford University Phase 1 Recruiting 22
David Miklos Stanford University Phase 1 Recruiting 60
Bijan Nejadnik SanBio, Inc. Phase 2 Completed 163
  • Epilepsy
 Cory Nicholas Neurona Therapeutics Phase 1 Recruiting 40
  • Sarcoma
 Theodore Nowicki University of California, Los Angeles Phase 1 Recruiting 12
  • Immune Disease
  • Leukocyte Adhesion Deficiency
 Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Active, not recruiting 9
  • B cell cancers
  • Leukemia
  • Leukemia, Acute Myeloid (AML)
 Matthew Porteus Stanford University Phase 1 Recruiting 22
Jana Portnow City of Hope, Beckman Research Institute Phase 1 Launching N/A
Saul Priceman City of Hope, Beckman Research Institute Phase 1 Recruiting 39
Michael Pulsipher Children's Hospital of Los Angeles Phase 1/2 Active, not recruiting 60
Gayatri Rao Rocket Pharmaceuticals, Inc. Phase 1 Closed 1
Antoni Ribas University of California, Los Angeles Phase 1 Recruiting 12
Judith Shizuru Stanford University Phase 1/2 Recruiting 40
William Sietsema Caladrius Biosciences Phase 2 Completed 113
Dennis Slamon University of California, Los Angeles Phase 1 Completed 48
Rachel Smith Capricor, Inc Phase 2 Closed 156
Gary Steinberg Stanford University Phase 1 Recruiting 30
Peter Stock University of California, San Francisco Phase 1/2 Recruiting 8
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Launching N/A
Clive Svendsen Cedars-Sinai Medical Center Phase 1/2 Completed 18
Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 13
William van der Touw Celularity Inc Phase 1/2 Active, not recruiting 86
Mark Walters University of California, San Francisco Phase 1 Launching N/A
Leo Wang City of Hope, Beckman Research Institute Phase 1 Recruiting 18
Irving Weissman Stanford University Phase 1 Completed 88
Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
David Williams Boston Children's Hospital Phase 2 Active, not recruiting 10
  • Leukemia, Acute Myeloid (AML)
 Joseph Woodard Immune-Onc Therapeutics Phase 1 Recruiting 122
Joseph Wu Stanford University Phase 1 Recruiting 18
  • Bladder or Urinary Tract Disorder
 James Yoo Wake Forest University Health Sciences Phase 1 Not yet recruiting 10
John Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
John Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
De-Fu Zeng City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 3
Icon for XLSX export